No Data
No Data
Express News | Enhua Pharmaceutical: Net profit increased 15.12% year-on-year in 2023, and plans to pay 10 to 3.2 yuan
Teva Pharmaceutical Investments Singapore, A Subsidiary Of Teva Pharmaceutical Industries And Jiangsu Nhwa Pharmaceutical Formed A Partnership To Market And Distribute Teva's Austedo (Deutetrabenazine) For Neurodegenerative And Movement Disorders
Teva Pharmaceutical Investments Singapore, A Subsidiary Of Teva Pharmaceutical Industries And Jiangsu Nhwa Pharmaceutical Formed A Partnership To Market And Distribute Teva's Austedo (Deutetrabenazine
Changes in US stocks | Tewa Pharmaceuticals rose more than 5% in the premarket and reached a strategic cooperation with Enhua Pharmaceuticals
Gelonghui Feb. 26 | TEVA.US (TEVA.US) rose 5.2% to $13.56 in the premarket. According to the news, Teva and Enhua Pharmaceutical recently held a signing ceremony for strategic cooperation between Teva and Enhua and joint commercialization cooperation with Antitan China at the Enhua Science and Technology Building. This cooperation marks an important step in the cooperation between the two sides in the field of neuropsychiatry.
A wholly-owned subsidiary of Enhua Pharmaceutical (002262.SZ) signed an exclusive commercialization license and cooperation agreement for Antitan products
Enhua Pharmaceutical (002262.SZ) announced that Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd., a wholly-owned subsidiary of the company (simplified...
Enhua Pharmaceutical (002262.SZ) passed the high-tech enterprise review
Gelonghui, February 6, 丨 Enhua Pharmaceutical (002262.SZ) announced that recently, the company successfully passed the high-tech enterprise review and received the “High-tech Enterprise Certificate” jointly issued by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, and the Jiangsu Provincial Taxation Bureau of the State Administration of Taxation. Certificate number: GR202332012741, date of issue: December 13, 2023, valid for three years.
Enhua Pharmaceutical (002262.SZ): Independent director Yin Xiaoxing voluntarily gave up receiving the independent director's allowance
Ge Longhui, January 9 | Enhua Pharmaceutical (002262.SZ) announced that it recently received a written statement from Mr. Yin Xiaoxing, an independent director of the company. From January 1, 2024 until the expiration date of the sixth board of directors of the company, Mr. Yin Xiaoxing voluntarily relinquished the independent director allowances that he could receive in the company due to serving as an independent director of the company's sixth board of directors and related positions in the special committee of the board of directors. At the same time, he promised that abandoning the above independent director allowances would not affect his normal performance as an independent director of the company, nor would it affect his normal performance of duties in the special committee of the board of directors. Related responsibilities in carrying out duties
No Data